AGC
AZN icon

Aspen Grove Capital’s AstraZeneca AZN Stock Holding History

Aspen Grove Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$447K Sell
2,371
-152
-6% -$28.6K 0.06% 121
2026
Q1 		$494K Buy
2,523
+397
+19% +$76.5K 0.1% 99
2025
Q4 		$391K Sell
2,126
-84
-4% -$14.7K 0.07% 114
2025
Q3 		$339K Sell
2,210
-1,000
-31% -$151K 0.06% 127
2025
Q2 		$449K Buy
3,210
+282
+10% +$39.5K 0.08% 124
2025
Q1 		$430K Buy
2,928
+1,248
+74% +$181K 0.08% 124
2024
Q4 		$220K Sell
1,680
-1,459
-46% -$204K 0.05% 182
2024
Q3 		$489K Buy
3,139
+145
+5% +$23.4K 0.11% 102
2024
Q2 		$467K Buy
2,994
+324
+12% +$48.8K 0.11% 106
2024
Q1 		$362K Buy
2,670
+26
+1% +$3.44K 0.1% 122
2023
Q4 		$347K Buy
2,644
+36
+1% +$4.68K 0.11% 111
2023
Q3 		$353K Buy
2,608
+858
+49% +$117K 0.13% 105
2023
Q2 		$250K Buy
+1,750
New +$257K 0.08% 162
2023
Q1 		– Sell
-2,214
Closed -$300K – 157
2022
Q4 		$300K Buy
+2,214
New +$278K 0.14% 112

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aspen Grove Capital's AZN Position: Q2 2026 in Review

Aspen Grove Capital reduced its AstraZeneca (AZN) stake by 6% in Q2 2026, selling an estimated $28.6K and leaving 2,371 shares worth $447K. The position accounts for 0.06% of the portfolio, ranked #121.

Aspen Grove Capital first reported a position in AZN in Q4 2022 and has held it in 14 quarters since. The position peaked at $494K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Aspen Grove Capital held 2,371 shares of AstraZeneca worth $447K as of Q2 2026.
  • Aspen Grove Capital sold 152 AstraZeneca shares in Q2 2026, an estimated $28.6K.
  • AstraZeneca made up 0.06% of Aspen Grove Capital's portfolio in Q2 2026, its #121 holding.
  • Aspen Grove Capital first reported a position in AstraZeneca in Q4 2022 and has held it in 14 quarters since.
  • Aspen Grove Capital's AstraZeneca position peaked at $494K in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Aspen Grove Capital's 13F filing for Q2 2026, filed 14 Aug 2026.